Women Digital Health

Investor Series: Opportunities in Women’s Digital Health Market

  • Lowest Price Guaranteed From USD 1,899

  • Published
    February 2023

  • Slides
    174

  • View Count
    988

  • Buy Now

Example Insights

Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Context-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Womens-Digital-Health-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Innovator-Landscape-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Company-Health-Indexing-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Value-Proposition-Analysis-thumb
Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Competitiveness-Analysis-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Analysis-of-Investments-thumb Investor-Series-Opportunities-in-Women’s-Digital-Health-Market-Funding-and-Investment-Analysis-thumb Investor-Series-Opportunities-in-Women’s-Digital-Health-Market-Seed-Investments-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Financial-Analysis-thumb
Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Financial-Ratios-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Stock-Performance-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Key-Indicators-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Technical-Analysis-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Financial-Overview-thumb
Investor-Series-Opportunities-in-Women’s-Digital-Health-Market-Distribution-by-Geography-thumb Investor-Series-Opportunities-in-Women’s-Digital-Health-Market-Key-Acquisition-Targets-thumb Investor-Series-Opportunities-in-Womens-Digital-Health-Market-Risk-Assessment-thumb Investor-Series-Opportunities-in-Women’s-Digital-Health-Market-Historical-Funding-Activity-thumb  

Overview

Digital health is a broad concept that encompasses telemedicine, teleconsultation, remote monitoring, connected devices, digital health platforms and health applications. The outbreak of COVID-19 pandemic has propelled the usage of digital technologies in order to receive healthcare, remotely. The revolutionary developments in digital health have transformed medicine and biomedical science as well as promoted early disease diagnosis and treatment. In addition, several FemTech startups are focused on the development of products or offering services to women of all age groups dealing with issues related to pregnancy, periods and menopause. Owing to the increased adoption rate of digital solutions and rise in the demand for remote healthcare services, the companies involved in the women’s digital health domain have witnessed a surge in the investment activity, with capital investments worth more than USD 3 billion over the past few years. This has enabled the overall FemTech business to flourish. It is worth noting that, NC° Birth Control, developed by Natural Cycles, was the first application to receive approval from US FDA in 2018 and is CE marked in Europe. This application can be used as a method of contraception and to track menstrual cycles, regularly. Subsequently, in 2021, various other women’s digital health solutions received US FDA approvals, including Ava Fertility Tracker (first approved fertility tracking wearable) and Clue (period tracking and birth control app).

Currently, more than 200 women’s digital health solutions, including applications / software, wearable devices, and services have been marketed / are under development with applications across various therapeutic areas including, reproductive health / fertility, menstrual cycle, general wellness, pelvic care and fetal health. These digital health solutions provide motivational support and inculcate healthy lifestyle changes in the target patient population. In addition, by advocating more personalized and meaningful treatment for women, employers may advance health equity and aid in the eradication of healthcare inequities. Given the increasing research efforts and active involvement of investors, we anticipate the development of a variety of applications and devices focused on improving women’s health, in the coming years. Further, taking into consideration both the historical and contemporary scenarios, we believe that the women’s digital health market presents lucrative investment opportunities for both short and long term investors.

Scope of the Report

The Investor Series: Opportunities in Women’s Digital Health Market (Focus on Innovator Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Key Acquisition Targets, Business Risk Assessment and Return on Investments) report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:

  • An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain.
  • A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.
  • An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products.
  • Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
  • An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value.
  • A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment.
  • An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.
  • A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks).
  • A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with the women’s digital health market, over the coming decades. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity within the women’s digital health market have further been segmented across type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

EXCEL DELIVERABLE

Spreadsheet I includes details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. In addition, the deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated.

Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights related to the capital investments made in the women’s digital health domain (since 2011).

Spreadsheet III is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies’ dataset.

Spreadsheet IV is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the women’s digital health market.

Spreadsheet V includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on the likely return on investments received by the mentioned investors.

POWERPOINT DELIVERABLE

Chapter 1 provides a brief summary of the content presented in the report, beginning with the trends associated with the rapidly growing women’s digital health market. Further, some of the key benefits associated with women’s digital health solutions, have been presented. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years. 

Chapters 2 and 3 feature brief (pictorial) summaries of the project objectives and approach used for data collection and analysis, in this study. 

Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.

Section I: Introduction to Women’s Digital Health Solutions and Innovator Landscape
Chapter 5 presents an introduction to women’s digital health, highlighting the background about the origin and evolution of this domain, along with benefits of digital health technologies. It features the key application areas of the FemTech industry, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. Further, it includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives of key stakeholder companies (as stated in publicly available articles and validated through primary research). It concludes with a discussion on the prominent barriers to the development and success of women’s digital health solutions. 

Chapter 6 focuses on some of the innovators (companies established post-2006) and features detailed analysis of such companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture. 

Chapter 7 includes information on the various products / solutions offered by the companies captured in the report (listed in Chapter 6). Further, it features analysis based on number and types of products. 

Chapter 8 presents a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity and estimated revenues and profits) of the different innovator companies, based on the insights obtained from product landscape.

Chapter 9 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely product-related value, value to patients, developer value and outreach-related value we developed an empirical framework to quantify the value proposition of a business.

Chapter 10 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developers of women’s digital health solutions captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing and valuation exercise. 

Section II: Analysis of Investments
Chapter 11 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report. 

Section III: Financial Analysis of Key Public Ventures
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall women’s digital health market from a financial perspective and includes detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of publicly listed companies within the innovator landscape dataset. 

Chapter 13 includes detailed profiles of the public ventures engaged in the development of women’s digital health solutions. Each profile features a brief overview of the company, details on its management team, insight from its balance sheet (if available), information on product / service portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).

Section IV: Market Forecast and Opportunity Analysis
Chapter 14 features an insightful market forecast and opportunity analysis, highlighting the estimated current and future size of the overall women’s digital health market, during the period 2023-2035. The opportunity has been segregated on the basis of type of solution (applications / software, devices and services), therapeutic application area (fetal health, general wellness, menstrual cycle, pelvic care and reproductive health / fertility), and geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

Section V: Key Acquisition Targets, Business Risk Assessment and Return on Investments
Chapter 15 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets. 

Chapter 16 includes a case study on business risk assessment, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, financial / asset-related risks, product / technology risks and other risks.

Chapter 17 includes a case study wherein the investors have exited various women’s digital health-based ventures, offering insights on return on investments received (based on availability of data). The abovementioned estimates / details offer a perspective on how past investments have paid off for investors as company gradually went public, over time.

Chapter 18 provides a pictorial summary of the overall project, presenting insights on the market landscape, funding and investment activity, value proposition, key acquisition targets and the market opportunities in women’s digital health domain, across different global regions.

Chapter 19 is a set of appendices, that contains the table of contents, list of figures, tables, companies and organizations mentioned in the report.

Table Of Contents

EXCEL DELIVERABLE

1. INNOVATORS AND PRODUCTS DATASET 
1.1. Analysis Notes
1.2. Innovator Landscape 
1.3. Product Landscape 
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. AI – AVII Appendices

2. FUNDING AND INVESTMENT ANALYSIS
2.1. Capital Investments in Women’s Digital Health 
2.2. Summary Dashboard 
2.3. AI – AIV Appendices

3. FUNDAMENTAL AND TECHNICAL FINANCIAL ANALYSIS
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends. 

4. MARKET FORECAST AND OPPORTUNITY ANALYSIS 
4.1. Market Forecast and Opportunity Analysis: Summary
4.2. Market Forecast and Opportunity Analysis: Marketed Products Dataset
4.3. Market Forecast and Opportunity Analysis: Pricing Dataset
4.4. Market Forecast and Opportunity Analysis: Applications / Software (Base Scenario)
4.5. Market Forecast and Opportunity Analysis: Applications / Software (Conservative Scenario)
4.6. Market Forecast and Opportunity Analysis: Applications / Software (Optimistic Scenario)
4.7. Market Forecast and Opportunity Analysis: Devices (Base Scenario)
4.8. Market Forecast and Opportunity Analysis: Devices (Conservative Scenario)
4.9. Market Forecast and Opportunity Analysis: Devices (Optimistic Scenario)
4.10. Market Forecast and Opportunity Analysis: Services (Base Scenario)
4.11. Market Forecast and Opportunity Analysis: Services (Conservative Scenario)
4.12. Market Forecast and Opportunity Analysis: Services (Optimistic Scenario)
4.13. Market Forecast and Opportunity Analysis: Prevalence
4.14. Market Forecast and Opportunity Analysis: Validation
4.15. Market Forecast and Opportunity Analysis: Population Data
4.16. Market Forecast and Opportunity Analysis: UN World Population Data

5. RETURN ON INVESTMENTS 
5.1. Analysis Notes
5.2. Estimated RoI for Investors in Company A

POWERPOINT DELIVERABLE 

1. CONTEXT 

2. PROJECT OBJECTIVES

3. PROJECT APPROACH

4. EXECUTIVE SUMMARY

Section I: Introduction to Women’s Digital Health Solutions and Innovator Landscape 
5. THE WOMEN’S DIGITAL HEALTH MARKET
5.1. Overview
5.2. Importance of FemTech Industry
5.3. Digital Solutions focused on Women’s Health
5.4. Leading Products in Women’s Digital Health
5.5. Challenges in Women’s Digital Health

6. WOMEN’S DIGITAL HEALTH: INNOVATOR LANDSCAPE
6.1. Methodology
6.2. Innovators in the Women’s Digital Health Market
6.3. Analysis of Innovator Landscape
6.4. Concluding Remarks

7. WOMEN’S DIGITAL HEALTH: PRODUCT LANDSCAPE
7.1. List of Products: Information on Current Status of Development and Type of Product(s) / Solution(s)
7.2. Analysis of Product Landscape: Distribution by Current Status of Development and Type of Product(s) / Solution(s)
7.3. List of Products: Information on Regulatory Approval(s) and Therapeutic Application Area(s)
7.4. Analysis of Product Landscape: Distribution by Regulatory Approval(s) and Therapeutic Application Area(s)
7.5. List of Products: Information on Usage Period with respect to Pregnancy, Purpose(s) and End User(s)
7.6. Analysis of Product Landscape: Distribution by Usage Period with respect to Pregnancy, Purpose(s) and End User(s)

8. COMPANY HEALTH INDEXING
8.1. Company Health Indexing Methodology
8.2. Company Health Indexing Scoring
8.3. Company Health Indexing

9. VALUE PROPOSITION ANALYSIS
9.1. Overview and Methodology
9.2. Product-related Value
9.3. Value to Patients
9.4. Developer Value
9.5. Outreach-related Value
9.6. Concluding Remarks

10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Overview and Methodology
10.2. Women’s Digital Health Solution Developers: Company Competitiveness Analysis

Section II: Analysis of Investments 
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Overview
11.2. Analysis by Type of Funding
11.3. Analysis by Geography
11.4. Most Active Players and Popular Investors
11.5. Trends Across Various Funding Categories
11.6. Summary of Funding and Investments

Section III: Financial Analysis of Key Public Ventures 
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.1.1. Financial Ratios (Interpretation Guide): Liquidity Ratios
12.1.2. Financial Ratios (Interpretation Guide): Financial and Business Risk Ratios
12.1.3. Financial Ratios (Interpretation Guide): Turnover / Efficiency Ratios
12.1.4. Financial Ratios (Interpretation Guide): Profitability Ratios
12.1.5. Financial Ratios (Interpretation Guide): Market Value Ratios
12.1.6. Financial Ratios (Interpretation Guide): Stability Ratios

12.2. Fundamental Financial Analysis: List of Companies
12.2.1. Case Study 1
12.2.2. Case Study 2
12.2.3. Case Study 3

12.3. Technical Financial Analysis Overview
12.3.1. Technical Indicators (Interpretation Guide): Candlestick Charts
12.3.2. Technical Indicators (Interpretation Guide): Moving Averages
12.3.3. Technical Indicators (Interpretation Guide): Bollinger Band®
12.3.4. Technical Indicators (Interpretation Guide): Relative Strength Index
12.3.5. Technical Indicators (Interpretation Guide): William’s R Analysis
12.3.6. Technical Indicators (Interpretation Guide): Moving Average Convergence Divergence

12.4. Technical Financial Analysis: List of Companies
12.4.1. Case Study 1
12.4.2. Case Study 2
12.4.3. Case Study 3

13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Bonzun
13.1.1. Key Highlights
13.1.1.1. Company Overview
13.1.1.2. Key Executives
13.1.1.3. Insights from Balance Sheet
13.1.1.4. Product / Service Portfolio
13.1.1.5. Recent Developments

13.1.2. Key Financial Details
13.1.2.1. Company Investments
13.1.2.2. Company Fundamentals
13.1.2.3. Company Technicals

13.2. HeraMED
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Key Executives
13.2.1.3. Insights from Balance Sheet
13.2.1.4. Product / Service Portfolio
13.2.1.5. Recent Developments

13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals

13.3. Sera Prognostics
13.3.1. Key Highlights
13.3.1.1. Company Overview
13.3.1.2. Key Executives
13.3.1.3. Insights from Balance Sheet
13.3.1.4. Product / Service Portfolio
13.3.1.5. Recent Developments

13.3.2. Key Financial Details
13.3.2.1. Company Investments
13.3.2.2. Company Fundamentals
13.3.2.3. Company Technicals

Section IV: Market Forecast and Opportunity Analysis 
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Overview and Methodology
14.2. Global Women’s Digital Health Market, 2023-2035
14.3. Distribution Across Key Market Segments
14.3.1. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
14.3.1.1. Women’s Digital Health Market for Applications / Software, 2023-2035
14.3.1.2. Women’s Digital Health Market for Devices, 2023-2035
14.3.1.3. Women’s Digital Health Market for Services, 2023-2035

14.3.2. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
14.3.2.1. Women’s Digital Health Market for General Wellness, 2023-2035
14.3.2.2. Women’s Digital Health Market for Menstrual Cycle, 2023-2035
14.3.2.3. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035
14.3.2.4. Women’s Digital Health Market for Fetal Health, 2023-2035
14.3.2.5. Women’s Digital Health Market for Pelvic Care, 2023-2035

14.3.3. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
14.3.3.1. Women’s Digital Health Market in North America, 2023-2035
14.3.3.2. Women’s Digital Health Market in Europe, 2023-2035
14.3.3.3. Women’s Digital Health Market in Asia-Pacific, 2023-2035
14.3.3.4. Women’s Digital Health Market in Latin America, 2023-2035
14.3.3.5. Women’s Digital Health Market in Middle East and North Africa, 2023-2035

14.4. Women’s Digital Health Market for Applications / Software, 2023-2035
14.4.1. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
14.4.1.1. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035
14.4.1.2. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035
14.4.1.3. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035
14.4.1.4. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035
14.4.1.5. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035

14.4.2. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
14.4.2.1. Women’s Digital Health Applications / Software Market in North America, 2023-2035
14.4.2.2. Women’s Digital Health Applications / Software Market in Europe, 2023-2035
14.4.2.3. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035
14.4.2.4. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035
14.4.2.5. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035

14.5. Women’s Digital Health Market for Devices, 2023-2035
14.5.1. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
14.5.1.1. Women’s Digital Health Devices Market for General Wellness, 2023-2035
14.5.1.2. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035
14.5.1.3. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035
14.5.1.4. Women’s Digital Health Devices Market for Fetal Health, 2023-2035
14.5.1.5. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035

14.5.2. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
14.5.2.1. Women’s Digital Health Devices Market in North America, 2023-2035
14.5.2.2. Women’s Digital Health Devices Market in Europe, 2023-2035
14.5.2.3. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035
14.5.2.4. Women’s Digital Health Devices Market in Latin America, 2023-2035
14.5.2.5. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035

14.6. Women’s Digital Health Market for Services, 2023-2035
14.6.1. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
14.6.1.1. Women’s Digital Health Services Market for General Wellness, 2023-2035
14.6.1.2. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035
14.6.1.3. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035
14.6.1.4. Women’s Digital Health Services Market for Fetal Health, 2023-2035
14.6.1.5. Women’s Digital Health Services Market for Pelvic Care, 2023-2035

14.6.2. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
14.6.2.1. Women’s Digital Health Services Market in North America, 2023-2035
14.6.2.2. Women’s Digital Health Services Market in Europe, 2023-2035
14.6.2.3. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035
14.6.2.4. Women’s Digital Health Services Market in Latin America, 2023-2035
14.6.2.5. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035

Section V: Key Acquisition Targets, Business Risk Assessment and Return on Investments 
15. KEY ACQUISITION TARGETS
15.1. Overview and Methodology
15.2. List of Key Acquisition Targets – Company Strength
15.3. List of Key Acquisition Targets – Value Proposition
15.4. Key Acquisition Targets

16. BUSINESS RISK ASSESSMENT
16.1. Chapter Overview
16.2. Operations-related Risks
16.3. Product / Technology Risks
16.4. Business-related Risks
16.5. Financial / Asset-related Risks
16.6. Other Risks

17. RETURN ON INVESTMENTS
17.1. Overview and Methodology
17.2. Case Study

18. CONCLUSION

19. APPENDICES

List Of Figures

Figure 5.1. Women’s Digital Health: Benefits of Digital Health Technologies
Figure 5.2. Women’s Digital Health: Key Application Areas of FemTech Industry
Figure 5.3. Women’s Digital Health: Type of Product(s) / Solution(s) and Key Industry Players
Figure 5.4. Women’s Digital Health: Key Marketed Products
Figure 5.5. Prominent Barriers to the Development and Success of Women’s Digital Health Solutions
Figure 6.1. Innovator Landscape: Distribution by Year of Establishment
Figure 6.2. Innovator Landscape: Distribution by Type of Venture
Figure 6.3. Innovator Landscape: Distribution by Company Size
Figure 6.4. Innovator Landscape: Distribution by Type of Market
Figure 6.5. Innovator Landscape: Distribution by Number of Products
Figure 6.6. Innovator Landscape: Distribution by Geography
Figure 7.1. Product Landscape: Distribution by Current Status of Development
Figure 7.2. Product Landscape: Distribution by Type of Product(s) / Solution(s)
Figure 7.3. Product Landscape: Distribution by Regulatory Approval(s)
Figure 7.4. Product Landscape: Distribution by Therapeutic Application Area(s)
Figure 7.5. Product Landscape: Distribution by Usage Period with respect to Pregnancy
Figure 7.6. Product Landscape: Distribution by Purpose(s)
Figure 7.7. Product Landscape: Distribution by End User(s)
Figure 9.1. Product-related Value: Distribution of Companies by Value Offered and Experience
Figure 9.2. Product-related Value: Distribution of Companies Offering High Value
Figure 9.3. Value to Patients: Distribution of Companies by Value Offered and Experience
Figure 9.4. Value to Patients: Distribution of Companies Offering Very High Value
Figure 9.5. Developer Value: Distribution of Companies by Value Offered and Experience
Figure 9.6. Developer Value: Distribution of Companies Offering High and Very High Value
Figure 9.7. Outreach-related Value: Distribution of Companies by Value Offered and Experience
Figure 9.8. Outreach-related Value: Distribution of Companies Offering Very High Value
Figure 9.9. Value Proposition Analysis: Concluding Remarks
Figure 10.1. Company Competitiveness Analysis: Large Companies based in North America (Peer Group I)
Figure 10.2. Company Competitiveness Analysis: Mid-sized Companies based in North America (Peer Group II)
Figure 10.3. Company Competitiveness Analysis: Small Companies based in North America, 2009-2016 (Peer Group III)
Figure 10.4. Company Competitiveness Analysis: Small Companies based in North America, 2017-2022 (Peer Group IV)
Figure 10.5. Company Competitiveness Analysis: Large and Mid-sized Companies based in Europe (Peer Group V)
Figure 10.6. Company Competitiveness Analysis: Small Companies based in Europe, 2010-2016 (Peer Group VI)
Figure 10.7. Company Competitiveness Analysis: Small Companies based in Europe, 2017-2021 (Peer Group VII)
Figure 10.8. Company Competitiveness Analysis: Large and Mid-sized Companies based in Asia-Pacific and Rest of the World (Peer Group VIII)
Figure 10.9. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World, 2011-2017 (Peer Group IX)
Figure 10.10. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World, 2018-2020 (Peer Group X)
Figure 11.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, Pre-2013-2022 (USD Million)
Figure 11.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 11.3. Funding and Investment Analysis: Distribution of Instances by Type of Venture Capital Funding
Figure 11.4. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5. Funding and Investment Analysis: Distribution of Amount Invested by Venture Capital Funding (USD Million)
Figure 11.6. Funding and Investment Analysis: Geographical Distribution of Funding Instances
Figure 11.7. Funding and Investment Analysis: Geographical Distribution of Amount Invested (USD Million)
Figure 11.8. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 11.9. Funding and Investment Analysis: Most Active Players by Amount Raised (USD Million)
Figure 11.10. Funding and Investment Analysis: Most Active Investors by Number of Instances
Figure 11.11. Awards / Grants: Cumulative Instances and Amount Invested (USD Million)
Figure 11.12. Awards / Grants: Global Distribution of Amount Invested (USD Million)
Figure 11.13. Awards / Grants: Most Active Investors
Figure 11.14. Crowd Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 11.15. Crowd Funding: Global Distribution of Amount Invested (USD Million)
Figure 11.16. Seed Funding: Cumulative Instances and Amount Invested (USD Million)
Figure 11.17. Seed Funding: Global Distribution of Amount Invested (USD Million)
Figure 11.18. Seed Funding: Most Active Investors
Figure 11.19. Venture (Series A): Cumulative Instances and Amount Invested (USD Million)
Figure 11.20. Venture (Series A): Global Distribution of Amount Invested (USD Million)
Figure 11.21. Venture (Series A): Most Active Investors
Figure 11.22. Venture (Series B): Cumulative Instances and Amount Invested (USD Million)
Figure 11.23. Venture (Series B): Global Distribution of Amount Invested (USD Million)
Figure 11.24. Venture (Series B): Most Active Investors
Figure 11.25. Venture (Series C): Cumulative Instances and Amount Invested (USD Million)
Figure 11.26. Venture (Series C): Global Distribution of Amount Invested (USD Million)
Figure 11.27. Venture (Series C): Most Active Investors
Figure 11.28. Venture (Series D): Cumulative Instances and Amount Invested (USD Million)
Figure 11.29. Venture (Series D): Global Distribution of Amount Invested (USD Million)
Figure 11.30. Venture (Series D): Most Active Investors
Figure 11.31. Venture (Series E): Cumulative Instances and Amount Invested (USD Million)
Figure 11.32. Venture (Series E): Global Distribution of Amount Invested (USD Million)
Figure 11.33. Venture (Series E): Most Active Investors
Figure 11.34. Public Offering: Cumulative Instances and Amount Invested (USD Million)
Figure 11.35. Public Offering: Global Distribution of Amount Invested (USD Million)
Figure 11.36. Private Placement: Cumulative Instances and Amount Invested (USD Million)
Figure 11.37. Private Placement: Global Distribution of Amount Invested (USD Million)
Figure 11.38. Private Placement: Most Active Investors
Figure 11.39. Debt Financing: Cumulative Instances and Amount Invested (USD Million)
Figure 11.40. Debt Financing: Global Distribution of Amount Invested (USD Million)
Figure 11.41. Debt Financing: Most Active Investors
Figure 11.42. Capital Investments in Women’s Digital Health: Summary of Investments, 2011-2022
Figure 12.1. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Bonzun)
Figure 12.2. Fundamental Financial Analysis: Liquidity Ratios, 2-years Trend (Bonzun)
Figure 12.3. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 2-years Trend (Bonzun)
Figure 12.4. Fundamental Financial Analysis: Profitability Ratios, 2-years Trend (Bonzun)
Figure 12.5. Fundamental Financial Analysis: Market Value and Stability Ratios, 2-years Trend (Bonzun)
Figure 12.6. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (HeraMED)
Figure 12.7. Fundamental Financial Analysis: Liquidity Ratios, 5-years Trend (HeraMED)
Figure 12.8. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 5-years Trend (HeraMED)
Figure 12.9. Fundamental Financial Analysis: Profitability Ratios, 5-years Trend (HeraMED)
Figure 12.10. Fundamental Financial Analysis: Market Value and Stability Ratios, 5-years Trend (HeraMED)
Figure 12.11. Fundamental Financial Analysis: Annual Revenues and Key Balance Sheet Parameter-related Trends (Sera Prognostics)
Figure 12.12. Fundamental Financial Analysis: Liquidity Ratios, 3-years Trend (Sera Prognostics)
Figure 12.13. Fundamental Financial Analysis: Financial, Business Risk and Turnover / Efficiency Ratios, 3-years Trend (Sera Prognostics)
Figure 12.14. Fundamental Financial Analysis: Profitability Ratios, 3-years Trend (Sera Prognostics)
Figure 12.15. Fundamental Financial Analysis: Market Value and Stability Ratios, 3-years Trend (Sera Prognostics)
Figure 12.16. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Bonzun)
Figure 12.17. Technical Analysis: 5-Day Moving Average (Bonzun)
Figure 12.18. Technical Analysis: 10-Day Moving Average (Bonzun)
Figure 12.19. Technical Analysis: 50-Day Moving Average (Bonzun)
Figure 12.20. Technical Analysis: Bollinger Band® (Bonzun)
Figure 12.21. Technical Analysis: Relative Strength Index (Bonzun)
Figure 12.22. Technical Analysis: Williams %R (Bonzun)
Figure 12.23. Technical Analysis: Moving Average Convergence Divergence (Bonzun)
Figure 12.24. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (HeraMED)
Figure 12.25. Technical Analysis: 5-Day Moving Average (HeraMED)
Figure 12.26. Technical Analysis: 10-Day Moving Average (HeraMED)
Figure 12.27. Technical Analysis: 50-Day Moving Average (HeraMED)
Figure 12.28. Technical Analysis: Bollinger Band® (HeraMED)
Figure 12.29. Technical Analysis: Relative Strength Index (HeraMED)
Figure 12.30. Technical Analysis: Williams %R (HeraMED)
Figure 12.31. Technical Analysis: Moving Average Convergence Divergence (HeraMED)
Figure 12.32. Technical Analysis: Stock Price (Candlestick Chart) and Volume Traded (Sera Prognostics)
Figure 12.33. Technical Analysis: 5-Day Moving Average (Sera Prognostics)
Figure 12.34. Technical Analysis: 10-Day Moving Average (Sera Prognostics)
Figure 12.35. Technical Analysis: 50-Day Moving Average (Sera Prognostics)
Figure 12.36. Technical Analysis: Bollinger Band® (Sera Prognostics)
Figure 12.37. Technical Analysis: Relative Strength Index (Sera Prognostics)
Figure 12.38. Technical Analysis: Williams %R (Sera Prognostics)
Figure 12.39. Technical Analysis: Moving Average Convergence Divergence (Sera Prognostics)
Figure 13.1. Bonzun: Company Fundamentals
Figure 13.2. Bonzun: Company Technicals
Figure 13.3. HeraMED: Company Fundamentals
Figure 13.4. HeraMED: Company Technicals
Figure 13.5. Sera Prognostics: Company Fundamentals
Figure 13.6. Sera Prognostics: Company Technicals
Figure 14.1. Global Women’s Digital Health Market, 2023-2035 (USD Million)
Figure 14.2. Women’s Digital Health Market: Distribution by Type of Solution, 2023 and 2035
Figure 14.3. Women’s Digital Health Market for Applications / Software, 2023-2035 (USD Million)
Figure 14.4. Women’s Digital Health Market for Devices, 2023-2035 (USD Million)
Figure 14.5. Women’s Digital Health Market for Services, 2023-2035 (USD Million)
Figure 14.6. Women’s Digital Health Market: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.7. Women’s Digital Health Market for General Wellness, 2023-2035 (USD Million)
Figure 14.8. Women’s Digital Health Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.9. Women’s Digital Health Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.10. Women’s Digital Health Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.11. Women’s Digital Health Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.12. Women’s Digital Health Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.13. Women’s Digital Health Market in North America, 2023-2035 (USD Million)
Figure 14.14. Women’s Digital Health Market in Europe, 2023-2035 (USD Million)
Figure 14.15. Women’s Digital Health Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.16. Women’s Digital Health Market in Latin America, 2023-2035 (USD Million)
Figure 14.17. Women’s Digital Health Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.18. Women’s Digital Health Market for Applications / Software: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.19. Women’s Digital Health Applications / Software Market for General Wellness, 2023-2035 (USD Million)
Figure 14.20. Women’s Digital Health Applications / Software Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.21. Women’s Digital Health Applications / Software Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.22. Women’s Digital Health Applications / Software Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.23. Women’s Digital Health Applications / Software Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.24. Women’s Digital Health Market for Applications / Software: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.25. Women’s Digital Health Applications / Software Market in North America, 2023-2035 (USD Million)
Figure 14.26. Women’s Digital Health Applications / Software Market in Europe, 2023-2035 (USD Million)
Figure 14.27. Women’s Digital Health Applications / Software Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.28. Women’s Digital Health Applications / Software Market in Latin America, 2023-2035 (USD Million)
Figure 14.29. Women’s Digital Health Applications / Software Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.30. Women’s Digital Health Market for Devices: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.31. Women’s Digital Health Devices Market for General Wellness, 2023-2035 (USD Million)
Figure 14.32. Women’s Digital Health Devices Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.33. Women’s Digital Health Devices Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.34. Women’s Digital Health Devices Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.35. Women’s Digital Health Devices Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.36. Women’s Digital Health Market for Devices: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.37. Women’s Digital Health Devices Market in North America, 2023-2035 (USD Million)
Figure 14.38. Women’s Digital Health Devices Market in Europe, 2023-2035 (USD Million)
Figure 14.39. Women’s Digital Health Devices Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.40. Women’s Digital Health Devices Market in Latin America, 2023-2035 (USD Million)
Figure 14.41. Women’s Digital Health Devices Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 14.42. Women’s Digital Health Market for Services: Distribution by Therapeutic Application Area, 2023 and 2035
Figure 14.43. Women’s Digital Health Services Market for General Wellness, 2023-2035 (USD Million)
Figure 14.44. Women’s Digital Health Services Market for Menstrual Cycle, 2023-2035 (USD Million)
Figure 14.45. Women’s Digital Health Services Market for Reproductive Health / Fertility, 2023-2035 (USD Million)
Figure 14.46. Women’s Digital Health Services Market for Fetal Health, 2023-2035 (USD Million)
Figure 14.47. Women’s Digital Health Services Market for Pelvic Care, 2023-2035 (USD Million)
Figure 14.48. Women’s Digital Health Market for Services: Distribution by Key Geographical Regions, 2023 and 2035
Figure 14.49. Women’s Digital Health Services Market in North America, 2023-2035 (USD Million)
Figure 14.50. Women’s Digital Health Services Market in Europe, 2023-2035 (USD Million)
Figure 14.51. Women’s Digital Health Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 14.52. Women’s Digital Health Services Market in Latin America, 2023-2035 (USD Million)
Figure 14.53. Women’s Digital Health Services Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.1. Key Acquisition Targets: Comparison based on Qualifying Parameters
Figure 16.1. Business Risk Analysis: Operations-related Risks
Figure 16.2. Business Risk Analysis: Product / Technology Risks
Figure 16.3. Business Risk Analysis: Business-related Risks
Figure 16.4. Business Risk Analysis: Financial / Asset-related Risks
Figure 16.5. Business Risk Analysis: Other Risks
Figure 17.1. Returns on Investment: Reported by Selected Stakeholders in Sera Prognostics and Historical Funding Activity
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia-Pacific

List Of Tables

Table 6.1. List of Innovators in Women’s Digital Health Market
Table 7.1. List of Products: Information on Current Status of Development and Type of Product(s) / Solution(s)
Table 7.2. List of Products: Information on Regulatory Approval(s) and Therapeutic Application Area(s)
Table 7.3. List of Products: Information on Usage Period with respect to Pregnancy, Purpose(s) and End User(s)
Table 8.1. Company Health Indexing
Table 9.1. Value Proposition Analysis: List of Top Six players
Table 10.1. Company Competitiveness Analysis: Scoring of Parameters
Table 12.1. Fundamental Financial Analysis: List of Companies
Table 12.2. Technical Financial Analysis: List of Companies
Table 13.1. Bonzun: Insights from Balance Sheet
Table 13.2. HeraMED: Insights from Balance Sheet
Table 13.3. Sera Prognostics: Insights from Balance Sheet
Table 15.1. List of Women’s Digital Health Key Acquisition Targets (Company Strength)
Table 15.2. List of Women’s Digital Health Key Acquisition Targets (Value Proposition)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. #ANGELS
  2. 14W
  3. 15th Rock
  4. 1776 Ventures
  5. 1984 Ventures
  6. 2048 Ventures
  7. 3L
  8. 415 Ventures
  9. 4FO Ventures
  10. 500 Global
  11. 500 Startups
  12. 8VC
  13. 9Unicorns
  14. a thousand colibris
  15. AH trust
  16. Aavia
  17. Accorded
  18. ACME Capital
  19. Act One Ventures
  20. Activision Blizzard
  21. Acumen
  22. Ad Astra Ventures
  23. Adaptive Health Capital
  24. Aindra Systems
  25. Alife
  26. Alkemi Growth capital
  27. Allara
  28. AllBright
  29. AlleyCorp
  30. Alpha Femtech
  31. Alsace Business Angels
  32. Althea
  33. Altimeter Capital Management
  34. Altitude Ventures
  35. Alumni Ventures
  36. Amboy Street Ventures
  37. America's Seed Fund
  38. aMoon
  39. Amplo
  40. Anchorless Bangladesh
  41. Andera Partners
  42. Andreessen Horowitz
  43. Angeles Investment Advisors
  44. AngelList
  45. Ankur Capital
  46. Anthem
  47. AOA Dx
  48. AoI Ventures
  49. App Basic
  50. Apricity
  51. Arbor
  52. Arboretum Ventures
  53. ArlanWasHere Investments
  54. Artesian
  55. Ascension Ventures
  56. Aspivix
  57. Asset Management Ventures
  58. Astia Angels
  59. Astinno
  60. ATH Holding Company
  61. Atlantic Bridge
  62. Atlantic Health System
  63. Atlantic Therapeutics
  64. AtlasV
  65. Atomico
  66. Atreyu
  67. Aurora Health Care
  68. Ava
  69. Avaana Capital
  70. Avestria Ventures
  71. Awesome People Ventures
  72. aws Gründerfonds
  73. Axilor
  74. Baby2Body
  75. Babyscripts
  76. Backstage Capital
  77. Baker Bros. Advisors
  78. balance
  79. Balderton
  80. Band of Angels
  81. Banner Health
  82. BBG Ventures
  83. Beacon Angels
  84. BEENEXT
  85. Begin Capital
  86. Bellabeat
  87. Bethnal Green Ventures
  88. BGF
  89. Bia Med
  90. Bill & Melinda Gates Foundation
  91. Biowink
  92. Black Capital
  93. Black Pearl Global Investments
  94. Blackbird
  95. BlackRock
  96. Bloody Health
  97. Bloomer Tech
  98. Bloomlife
  99. Bloomth
  100. Blossom Capital
  101. Blue Cross Blue Shield of Massachusetts
  102. Blue Ocean Ventures
  103. Blue Ox Healthcare Partners
  104. BlueRun Ventures
  105. Blume Equity
  106. BNP Paribas
  107. Bolt Ventures
  108. BOND
  109. Bonnier Ventures
  110. Bonzun
  111. Borski Fund
  112. Bose Ventures
  113. BoxGroup
  114. Bramalea Partners
  115. Bread and Butter Ventures
  116. breathe ilo
  117. BrightCap Ventures
  118. Brilliantly
  119. Broadway Angels
  120. btov
  121. Business Angels Club Berlin-Brandenburg
  122. Business Angels Switzerland
  123. B-wom
  124. Cambia Health Solutions
  125. Cambridge Digital Health
  126. Canaan
  127. Candlelit
  128. Canopie
  129. Capier Investments
  130. Capital Angel Network
  131. Care4Cute
  132. CareSignal
  133. Carnrite Ventures
  134. Carrot Fertility
  135. Casdin Capital
  136. Catalyst Health Ventures
  137. Cayaba Care
  138. CG Health Ventures
  139. Chemo
  140. Cherubic Ventures
  141. Chiaroscuro Foundation
  142. Chione
  143. Chiratae Ventures
  144. Chorus Health
  145. Chrysalis
  146. Cigna Ventures
  147. Claritas Capital
  148. Clementine
  149. CM-CIC Innovation
  150. Coelius Capital
  151. Collaborative Fund
  152. Colle Capital
  153. Combine
  154. Commonfund
  155. Company Ventures
  156. Compound
  157. Connect
  158. Connecticut Innovations
  159. Core Innovation Capital
  160. Cormorant Asset Management
  161. Coroflo
  162. Correlation Ventures
  163. Cortado Ventures
  164. Crescent Ridge
  165. CrunchFund
  166. CRV
  167. CU Healthcare Innovation Fund
  168. Deerfield
  169. Define Ventures
  170. Development Bank of Wales
  171. Digitalis Ventures
  172. DigiTx Partners
  173. DilenyTech
  174. Domain Associates
  175. Downing Ventures
  176. Dragoneer Investment Group
  177. Draper Associates
  178. Dream Incubator
  179. DSM Venturing
  180. Earlybird Venture Capital
  181. Ease Healthcare
  182. Easton Capital Investment Group
  183. Echo Health Ventures
  184. EIT Health
  185. ElaWoman
  186. Elda Health
  187. Eldridge
  188. Eli Health
  189. Elidah
  190. EloCare
  191. e-L?vu Health
  192. Elvie
  193. Elysium Venture Capital
  194. Embr Labs
  195. Embria
  196. Emme (a part of SimpleHealth)
  197. Endeavour Vision
  198. Endodiag
  199. Endometrix
  200. ENSE Group
  201. Enterprise Ireland
  202. Enzia Ventures
  203. Episcopal Health Foundation
  204. EQT Ventures
  205. eQventure
  206. Established Ventures
  207. European Commission
  208. European Innovation Council and SMEs Executive Agency (EISMEA)
  209. Evernow
  210. Exandus
  211. Exor
  212. F Cubed
  213. Felix Capital
  214. Female Founders Fund
  215. Femcare Fertility
  216. Femcy
  217. FemHealth Ventures
  218. FEMM
  219. Femna Health
  220. Femometer
  221. FemTech Healthcare
  222. FemX
  223. fermata
  224. Ferne Health
  225. FetoLife
  226. Firestartr
  227. First Round Capital
  228. FirstCheck Africa
  229. FirstMark
  230. Fizimed
  231. Flanders Innovation and Entrepreneurship (VLAIO)
  232. Flare Capital Partners
  233. Flint Capital
  234. Flo Health
  235. Flo Living
  236. Flöka
  237. Foothill Ventures
  238. Forerunner
  239. Formation 8
  240. Fors Marsh
  241. Fortunis Capital
  242. Foundation for Technological Innovation
  243. Founders Fund
  244. Foview
  245. F-Prime
  246. Frame Fertility
  247. Freemark Financial
  248. Froedtert & the Medical College of Wisconsin
  249. Frøya Life
  250. Fuel Ventures
  251. Future Positive Capital
  252. Future\Perfect Ventures
  253. Gaingels
  254. Gals Bio
  255. gBETA Medtech
  256. General Catalyst
  257. General Electric
  258. Gennev
  259. GingerBread Capital
  260. Giving Wings
  261. Global Founders Capital
  262. Global Sources
  263. Glow
  264. Golden Seeds
  265. Goldman Sachs
  266. Goodgrower
  267. Google Ventures
  268. Gopher Asset Management
  269. Grand Central Tech
  270. Great Oaks Venture Capital
  271. Green D Ventures
  272. Greycroft
  273. Groupe Arnault
  274. GSK
  275. Hackster
  276. Halza
  277. Hambrecht Ducera Growth Ventures
  278. Harmony Partners
  279. Hatteras Venture Partners
  280. Haxus
  281. Headline
  282. Health & Her
  283. Health Enterprise Partners
  284. Health in Her Hue
  285. HealthTech Capital
  286. HeraMED
  287. Hikma Ventures
  288. Hiro Capital
  289. Hiventures
  290. HLM Venture Partners
  291. Homebrew
  292. Horizon 2020
  293. Houston Angel Network (HAN)
  294. Hoxton Ventures
  295. Hubble Connected
  296. Human Ventures
  297. Humbition
  298. Hustle Fund
  299. HVF
  300. IA Ventures
  301. IBB Capital
  302. iBreve
  303. Icon Ventures
  304. Illumigyn
  305. Illumina Ventures
  306. iMama
  307. Impact Ventures
  308. Index Ventures
  309. Information Technology Academia Collaboration (ITAC)
  310. Initialized Capital
  311. Inito
  312. inne
  313. InnovaHealth Partners
  314. Innovate UK
  315. Inova
  316. Insignia Ventures Partners
  317. Inspired Capital
  318. InterWest Partners
  319. Invest Ottawa
  320. IPGL
  321. iSeed Capital
  322. iSono Health
  323. Iterative
  324. iXensor
  325. January Ventures
  326. Jennis
  327. Johnson & Johnson Innovation
  328. Joyance Partners
  329. JumpStart
  330. Kamet Ventures
  331. Kapor Capital
  332. kegg
  333. Kensington Capital Partners
  334. Kheiron Medical Technologies
  335. Khyria
  336. Kimera
  337. Kindbody
  338. KMG Partners
  339. KOFA Healthcare
  340. Konna
  341. KYTO Technology & Life Science
  342. Labcorp
  343. LabQ International
  344. Lactamo
  345. LactApp
  346. Lactation Lab
  347. Laerdal Medical
  348. Laia
  349. Lanza techVentures
  350. LaunchCapital
  351. Launchpad Venture Group
  352. Leap Fitness Group
  353. Leerink Transformation Partners
  354. Lemonaid Health
  355. LetsGetChecked
  356. LifeSense Group (LSG)
  357. Lightbank
  358. Lightship Capital
  359. Lightstone Ventures
  360. Linchpin Technologies
  361. LionBird
  362. Lisa Health
  363. Livia
  364. Logos Capital
  365. LOI Venture
  366. Lone Pine Capital
  367. Longmeadow Capital Partners
  368. Longwood Fund
  369. Looking Glass Capital
  370. Lovetap
  371. Lucina Analytics
  372. Luminary Labs
  373. Lux Capital
  374. Mabel
  375. Mae
  376. MagicGirl
  377. Magnetic Ventures
  378. Mahmee
  379. Maki.vc
  380. Mangrove Capital Partners
  381. MassChallenge
  382. Material Impact
  383. Materna Medical
  384. Maven Clinic
  385. Maveron
  386. Maya Digital Health
  387. Mayo Clinic
  388. MBX Capital
  389. MegaForce
  390. MEMEDA
  391. MemorialCare Innovation Fund
  392. Menopod
  393. Merchavia Holdings and Investments
  394. Meridian Street Capital
  395. Meritech
  396. Metrodora Ventures
  397. Metronomic Health
  398. MiMARK
  399. Mira
  400. MobileODT
  401. Monashee Investment Management
  402. Monkfish Equity
  403. Monk's Hill Ventures
  404. MooDoos Investments
  405. Moonai
  406. Mordern Fertility (a subsidiary of Ro)
  407. Mosaic Ventures
  408. Muse Capital
  409. MUTU
  410. MyAva
  411. Nabta Health
  412. Nascent Invest
  413. National Cancer Institute (NCI)
  414. National Institutes of Health
  415. National Science Foundation (NSF)
  416. Natural Cycles
  417. Naytal
  418. NC IDEA
  419. NEA
  420. Nest Collaborative
  421. NextCell Pharma
  422. Nexus Venture Partners
  423. NFP
  424. NGP Capital
  425. Niramai
  426. Novartis Venture Fund
  427. NueCura Partners
  428. Nueterra Capital
  429. NursElet
  430. Nuvo
  431. Oak HC/FT
  432. Oath Care
  433. OCON Healthcare
  434. Octopus Ventures
  435. Olive Tree Ventures
  436. OMERS Ventures
  437. One Brave Idea
  438. Oova
  439. Optum Ventures
  440. OrbiMed
  441. Ordinary Folk
  442. Orios Venture Partners
  443. Orreco
  444. Osage University Partners
  445. OSF Ventures
  446. Oula
  447. Ovia Health
  448. Ovira
  449. Ovulai
  450. Ovulation Calculator
  451. P5 Health Ventures
  452. Pachamama
  453. Parentlane
  454. Parian Global Management
  455. Partech
  456. PBJ Capital
  457. Peanut
  458. Pepapp
  459. Perceptive Advisors
  460. Perigee
  461. Philips
  462. pi Ventures
  463. Pioneer Fund
  464. Pipeline Angels
  465. Plackal
  466. Plug and Play
  467. Polytech Ventures
  468. Pomelo Care
  469. Pontifax
  470. Portfolia
  471. Precursor Ventures
  472. PregnaScan
  473. Prima-Temp
  474. Prime Venture Partners
  475. Proactive for her
  476. Promus Ventures
  477. Proov
  478. Providence Ventures
  479. pumpspotting
  480. Punchbowl
  481. Pura Vida
  482. Purple Arch Ventures
  483. Qiming Venture Partners
  484. Radical Ventures
  485. Raiing Medical
  486. Raydiant Oximetry
  487. Refactor Capital
  488. Renalis
  489. Renovia
  490. Revolution
  491. Rhia Ventures
  492. Ro
  493. Rock Health
  494. Rock Springs Capital
  495. ROHTO Pharmaceutical
  496. RRE Ventures
  497. Safar Partners
  498. Santora Nakama
  499. SDVentures
  500. Seae Ventures
  501. Seashore Solutions
  502. Sequoia
  503. Sera Prognostics
  504. Seroba Life Sciences
  505. Seven Seven Six
  506. Sevenlogics
  507. SFC Capital
  508. Shareholder Value Management
  509. Shatter Fund
  510. ShawSpring Partners
  511. She Raises Capital
  512. Sherpa Ventures
  513. SideCar Angels
  514. SignalFire
  515. Silicon Valley Bank
  516. Sinai Ventures
  517. Slow Ventures
  518. Social Starts
  519. Softtech Ventures
  520. Sonrava Health
  521. SOSV
  522. Sound Ventures
  523. Special Situations Life Sciences Innovation Fund
  524. Spring Mountain Capital
  525. Springbank Collective
  526. SRI International
  527. Srirakshaa Healthcare
  528. St. George Bank
  529. Starting Line
  530. Start-Up Chile
  531. StartUp Health
  532. Startup Karnataka
  533. SteadySense
  534. SteelSky Ventures
  535. Storka
  536. Sunstone Partners
  537. SV Angel
  538. SVC
  539. Sweet Capital
  540. Swisscom Ventures
  541. Syrona Health
  542. Tamtris Web Services
  543. Tara Health Foundation
  544. Target Global
  545. TBD Angels
  546. Techammer
  547. Techstars
  548. Tempdrop
  549. Teneo
  550. Texas HALO Fund
  551. Texas Medical Center Innovation
  552. The Baupost Group
  553. The Body Literacy Collective
  554. The Chernin Group
  555. The Female Health Hub
  556. The Handler
  557. The Helm
  558. The Kresge Foundation
  559. The Lily Project
  560. The Osiris Group
  561. The Pelvic Expert
  562. The Sputnik Group
  563. Think Bigger Capital
  564. Third Culture Capital (3CC)
  565. Threshold Ventures
  566. Tia
  567. Tiger Global Management
  568. Titan Capital
  569. TMV
  570. Together For Her
  571. Torch Capital
  572. TQ Ventures
  573. Transformation Capital
  574. Trimble Ventures
  575. Tristel
  576. TruDiary
  577. True Ventures
  578. TT Capital Partners
  579. Tusk Venture Partners
  580. U.S. Venture Partners
  581. Ubicom (acquired by Qualcomm)
  582. Uncork Capital
  583. Union Square Ventures
  584. UnityPoint Health Ventures
  585. Universal Music Group
  586. University Hospitals
  587. UpStart VC
  588. Uvi Health
  589. Vcapital
  590. Vectr
  591. Veera Health
  592. Vega Ventures
  593. Velmio
  594. Venrex
  595. Venture Kick
  596. Vertex Ventures Southeast Asia and India
  597. Victorum Capital
  598. Viento Capital
  599. Villgro
  600. Virginia Venture Partners
  601. Vivant
  602. Vivo Capital
  603. VNV Global
  604. Wachanga
  605. Walking Ventures
  606. Watkins-Conti Products
  607. Wavemaker Three-Sixty Health
  608. WCC Partners
  609. Westerly Winds
  610. Western Development Commission
  611. Western Technology Investment
  612. Wildflower Health
  613. Willow
  614. Winklevoss Capital
  615. Women's Venture Fund
  616. WOMENUP
  617. WOOM (a subsidiary of Apricity)
  618. XA Network
  619. XYZ Venture Capital
  620. Y Combinator
  621. Yesmom
  622. Yozma
  623. Ysios Capital
  624. Zaya Care
  625. Zero Mothers Die
  626. Zoie Health
  627. Zu?rcher Kantonalbank

Source 1: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499383/

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.